Vaccination induces broadly neutralizing antibody precursors to HIV gp41
A key barrier to the development of vaccines that induce broadly neutralizing antibodies (bnAbs) against human immunodeficiency virus (HIV) and other viruses of high antigenic diversity is the design of priming immunogens that induce rare bnAb-precursor B cells.
Novel vaccine concept generates immune responses that could produce multiple types of HIV neutralizing antibodies
Transmission electron micrograph of HIV-1 virus particles (pink/tan) budding and replicating from a segment of a chronically infected H9 cell (teal).
Top 10 HIV Clinical Developments of 2023
It is inevitable that in a not-too-distant future, most people with HIV who live in richer nations will control their infection with medications that emerge from the end of a needle.
Are we winning the war on AIDS?
New HIV infection rates are falling, and treatments are improving. But do we have the political will to end HIV/AIDS?
Lenacapavir for HIV-1 — Potential Promise of a Long-Acting Antiretroviral Drug
The Research Department at North Texas ID Consultants is proud to be listed in the New England Journal of Medicine as collaborators with this new, and exciting long acting antiretrovirals for the treatment of HIV.
